Search clinical trials for: Recombinant novel coronavirus vaccine (CHO cell)

Total 158 results

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Active, not recruiting

Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)

Coronavirus Disease 2019

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Not yet recruiting

Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Coronavirus
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Coronavirus

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Zhejiang Provincial Center for Disease Control and Prevention

Completed

Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Zhejiang Provincial Center for Disease Control and Prevention

Recruiting

Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization

Prevention of COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization

Prevention of COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Recruiting

A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)

COVID-19

Uzbekistan
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Beijing Chao Yang Hospital; The Second Affiliated Hospital of Chongqing Medical...

Unknown

Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine

Coronavirus

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Unknown

Clinical Study of Recombinant Novel Coronavirus Vaccine

Coronavirus

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Unknown

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)

Coronavirus

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

Coronavirus

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Active, not recruiting

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

Safety and Efficacy | Prevention of COVID-19

China, Ecuador, Indonesia, Pakistan, Uzbekistan
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Hunan Provincial Center for Disease Control and Prevention

Not yet recruiting

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

COVID-19
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Hunan Provincial Center for Disease Control and Prevention; Guizhou Center... and other collaborators

Recruiting

Safety Study of COVID19 Vaccine on the Market

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Recruiting

Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)

Coronavirus Disease 2019

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity

Coronavirus Disease 2019

China
CanSino Biologics Inc.
Jiangsu Province Centers for Disease Control and Prevention; Beijing Institute...

Completed

A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

COVID-19

China
CanSino Biologics Inc.
Jiangsu Province Centers for Disease Control and Prevention

Completed

A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.

COVID-19

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine

Coronavirus Disease 2019

China
CanSino Biologics Inc.
Tongji Hospital; Jiangsu Province Centers for Disease Control and Prevention; Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China and other collaborators

Completed

Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults (CTCOVID-19)

COVID-19

China
NPO Petrovax
CanSino Biologics Inc.

Completed

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

Covid19

Russian Federation
CanSino Biologics Inc.
Beijing Institute of Biotechnology

Completed

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

COVID-19

Mexico, Argentina, Chile, Pakistan, Russian Federation
CanSino Biologics Inc.
Beijing Institute of Biotechnology; Canadian Center for Vaccinology

Unknown

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

COVID-19

Canada
Fundación Huésped
CanSino Biologics Inc.; Canadian Center for Vaccinology; Hospital Fernandez

Recruiting

Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older. (COVID-19)

Covid19

Argentina
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological... and other collaborators

Recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
WestVac Biopharma Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

COVID-19

China
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological...

Active, not recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Active, not recruiting

A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19

COVID-19

China
Institute of Biotechnology, Academy of Military...
Zhongnan Hospital; Jiangsu Province Centers for Disease Control and Prevention and other collaborators

Completed

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV)

COVID-19

China
WestVac Biopharma Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)

COVID-19

China
CanSino Biologics Inc.
Jiangsu Province Centers for Disease Control and Prevention; Beijing Institute...

Completed

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

COVID-19

China
CanSino Biologics Inc.
Beijing Institute of Biotechnology

Terminated

A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

COVID-19

Chile
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)

COVID-19

United Arab Emirates
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
First Affiliated Hospital Bengbu Medical College

Completed

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

COVID-19

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

COVID-19

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Terminated

Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older

COVID-19

China
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Herpes Zoster

China
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)

Herpes Zoster

Philippines
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

COVID-19

Russian Federation, Nepal
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Chronic Renal Failure With Hemodialysis

China
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)

COVID-19

Philippines
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

COVID-19

United Arab Emirates
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Herpes Zoster

China
Jiangsu Rec-Biotechnology Co., Ltd.
Iqvia Pty Ltd

Completed

Safety, Reactogenicity and Immunogenicity Study of ReCOV

Covid19

New Zealand
Shenyang Sunshine Pharmaceutical Co., LTD.

Recruiting

Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure

Hemodialysis | Kidney Failure, Chronic

China
WestVac Biopharma Co., Ltd.
WestVac Biopharma (Guangzhou) Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

COVID-19

China

Search clinical trials for: Recombinant novel coronavirus vaccine (CHO cell)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations